Previous studies have shown that the traditional herbal complex Gosha-jinki-gan (GJG) improves diabetic neuropathy and insulin resistance. The present study was undertaken to elucidate the molecular mechanisms related with the long-term effects of GJG administration on insulin action in vivo and the early steps of insulin signaling in skeletal muscle in streptozotocin (STZ) diabetes. Rats were randomized into five subgroups: (1) saline treated control, (2) GJG treated control, (3) 2-unit insulin + saline treated diabetic, (4) saline + GJG treated diabetic and (5) 2-unit insulin + GJG treated diabetic groups. After seven days of treatment, euglycemic clamp experiment at an insulin infusion rate of 6 mU/kg/min was performed in overnight fasted rats. Despite the 2-unit insulin treatment, the metabolic clearance rates of glucose (MCR, ml/kg/min) in diabetic rats were significantly lower compared with the controls (11.4 +/- 1.0 vs 44.1 +/- 1.5; P < 0.001), and were significantly improved by insulin combined with GJG or GJG alone (26 +/- 3.2 and 24.6 +/- 2.2, P < 0.01, respectively). The increased insulin receptor (IR)-beta protein content in skeletal muscle of diabetic rats was not affected by insulin combined with GJG administration. However, the decreased insulin receptor substrate-1 (IRS-1) protein content was significantly improved by treatment with GJG. Additionally, the increased tyrosine phosphorylation levels of IR-beta and IRS-1 were significantly inhibited in insulin combined with GJG treated diabetes. The present results suggest that the improvement of the impaired insulin sensitivity in STZ-diabetic rats by administration of GJG may be due, at least in part, to correction in the abnormal early steps of insulin signaling in skeletal muscle.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC538504PMC
http://dx.doi.org/10.1093/ecam/neh028DOI Listing

Publication Analysis

Top Keywords

gjg treated
16
insulin
15
insulin signaling
12
skeletal muscle
12
2-unit insulin
12
treated diabetic
12
insulin combined
12
combined gjg
12
gjg
11
herbal complex
8

Similar Publications

Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite.

N Engl J Med

November 2024

From Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden (O.A.C.L., B.M.D.F-.F., J.P.R.K., G.V.T.R., J.J.J., S.C.C.-M., F.J.A.G., H.M.B.-R., E.I., E.C., E.W., E.L.H., R.M., C.J.J., M.R.), and the Department of Medical Microbiology, Radboud University Medical Center, Nijmegen (G.-J.G., M.V.-B., W.G., T.R.S., B.G.M., T.B., M.B.B.M.) - both in the Netherlands.

Background: Currently licensed and approved malaria subunit vaccines provide modest, short-lived protection against malaria. Immunization with live-attenuated malaria parasites is an alternative vaccination strategy that has potential to improve protection.

Methods: We conducted a double-blind, controlled clinical trial to evaluate the safety, side-effect profile, and efficacy of immunization, by means of mosquito bites, with a second-generation genetically attenuated parasite (GA2) - a single knockout NF54 parasite (sporozoite form) with extended development into the liver stage.

View Article and Find Full Text PDF
Article Synopsis
  • Development of chemotherapy-induced peripheral neuropathy (CIPN) can complicate cancer treatment, leading to dose reductions or stopping therapy; Goshajinkigan (GJG), a traditional Japanese medicine, may help reduce these symptoms.
  • A study with 55 ovarian cancer patients tested two groups: one started GJG after experiencing grade 2 neuropathy, while the other took it a week before chemotherapy; the main goals were to assess sensory neuropathy severity and pain levels.
  • Results showed that patients starting GJG early (Group B) had fewer pain complaints, lower reliance on pain medications, and less persistent neuropathy six months later, suggesting that preventive use of GJG could be beneficial, but more research is needed for confirmation
View Article and Find Full Text PDF
Article Synopsis
  • CCL17 is a protein that affects inflammation and pain, and GSK3858279 is a new antibody that targets it to help with pain relief.
  • A study was done on healthy adult males to see if GSK3858279 could reduce pain better than a placebo (a fake treatment).
  • The results showed that there wasn’t a big difference in pain relief between GSK3858279 and the placebo, but it was safe and didn’t cause serious problems for the participants.
View Article and Find Full Text PDF

Background: Paclitaxel (PTX) is an essential cytotoxic anticancer agent and a standard treatment regimen component for various malignant tumors, including advanced unresectable non-small cell lung cancer, thymic cancer, and primary unknown cancers. However, chemotherapy-induced peripheral neuropathy (CIPN) caused by PTX is a significant adverse event that may lead to chemotherapy discontinuation and deterioration of the quality of life (QOL). Although treatment modalities such as goshajinkigan (GJG), pregabalin, and duloxetine are empirically utilized for CIPN, there is no established evidence for an agent as a preventive measure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!